AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $228.26, giving the company a market capitalization of 403.42B. It carries a P/E multiple of 168.97 and pays a dividend yield of 2.9%.
As of 2026-01-08, AbbVie(ABBV) stock has fluctuated between $226.40 and $231.54. The current price stands at $228.26, placing the stock +0.8% above today's low and -1.4% off the high.
The AbbVie(ABBV)'s current trading volume is 2.76M, compared to an average daily volume of 4.84M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
AbbVie says it’s not in talks to buy Revolution Medicines; WSJ reports another suitor may prevail AbbVie says it “is not in discussions” to acquire oncology bi...
Claim 70% Off TipRanks Premium Xilio Therapeutics ( (XLO) ) has provided an announcement. On January 8, 2026, Xilio Therapeutics reported a series of corporat...
Wolfe Research downgraded AbbVie (ABBV) to Peer Perform from Outperform without a price target The firm believes the shares already reflect expectations for out...
Analyst ratings
65%
of 31 ratingsMore ABBV News
Wolfe Research downgraded AbbVie (ABBV) to Peer Perform from Outperform. Published first on TheFly – the ultimate source for real-time, market-moving breaking...
AbbVie Inc. ( ) will increase its dividend from last year's comparable payment on the 17th of February to $1.73. Based on this payment, the dividend yield for t...
AbbVie (ABBV) said it's not in talks to buy Revolution Medicines (RVMD). Shares of Revolution Medicines sunk 14% in after-hours trading. “AbbVie is not in disc...
HDV returned 11.3% over the past year versus 17% for the S&P 500 and underperformed by 100 percentage points over 10 years. AbbVie represents 6.2% of the fund...
AbbVie, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Yee from UBS maintained a Hold rating on the stock and...
AbbVie recently entered a global collaboration and license option agreement with China’s Zelgen Pharma for ZG006, granting AbbVie exclusive rights to develop an...
AbbVie pays $6.56 in dividends against only $1.33 in earnings per share due to Humira patent loss. DHS returned 17.6% over the past year but its monthly distri...